• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

消除宫颈癌。90:70:90。我们携手共进。

Cervical Cancer Elimination. 90:70:90. Together We Can.

作者信息

Purandare C N

机构信息

Obstetrician and Gynaecologist, Purandare Hospital, Mumbai, India.

出版信息

J Obstet Gynaecol India. 2024 Aug;74(4):292-294. doi: 10.1007/s13224-024-02052-x. Epub 2024 Aug 31.

DOI:10.1007/s13224-024-02052-x
PMID:39280207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11399510/
Abstract

Cervical cancer elimination is a global health priority with the ambitious 90:70:90 target set by the WHO. This initiative aims for 90% of girls to be vaccinated against HPV, 70% of women to be screened with a high-performance test, and 90% of those who test positive to receive appropriate treatment by 2030. This editorial reflects on the journey from the initial declaration in 2018 to the present, highlighting the progress, challenges, and future directions in the fight against cervical cancer. With significant contributions from organizations like FIGO and FOGSI, the introduction of cost-effective vaccines and advanced screening methods, we are on a path towards achieving our targets. However, persistent efforts and global collaboration are essential to overcome the remaining hurdles.

摘要

消除宫颈癌是一项全球卫生重点工作,世界卫生组织设定了宏伟的90:70:90目标。该倡议旨在到2030年使90%的女孩接种人乳头瘤病毒(HPV)疫苗,70%的妇女接受高效检测筛查,以及90%检测呈阳性者获得适当治疗。这篇社论回顾了从2018年最初宣布至今的历程,突出了抗击宫颈癌过程中的进展、挑战和未来方向。在国际妇产科联盟(FIGO)和印度妇产科医师协会(FOGSI)等组织的大力贡献下,随着具有成本效益的疫苗和先进筛查方法的引入,我们正朝着实现目标的道路迈进。然而,持续努力和全球合作对于克服剩余障碍至关重要。

相似文献

1
Cervical Cancer Elimination. 90:70:90. Together We Can.消除宫颈癌。90:70:90。我们携手共进。
J Obstet Gynaecol India. 2024 Aug;74(4):292-294. doi: 10.1007/s13224-024-02052-x. Epub 2024 Aug 31.
2
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.接种人乳头瘤病毒预防性疫苗以预防宫颈癌及其癌前病变。
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
3
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
4
Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.移民人群中人类乳头瘤病毒疫苗接种的驱动因素及提高覆盖率的干预措施:一项系统评价和荟萃分析
Lancet Public Health. 2025 Aug;10(8):e693-e711. doi: 10.1016/S2468-2667(25)00148-3.
5
Factors that influence caregivers' and adolescents' views and practices regarding human papillomavirus (HPV) vaccination for adolescents: a qualitative evidence synthesis.影响照顾者和青少年对青少年人乳头瘤病毒(HPV)疫苗接种的看法及做法的因素:一项定性证据综合分析
Cochrane Database Syst Rev. 2025 Apr 15;4(4):CD013430. doi: 10.1002/14651858.CD013430.pub2.
6
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.1980年至2023年全球、区域和国家儿童常规疫苗接种覆盖率趋势及2030年预测:2023年全球疾病负担研究的系统分析
Lancet. 2025 Jun 24. doi: 10.1016/S0140-6736(25)01037-2.
7
Sexual Harassment and Prevention Training性骚扰与预防培训
8
[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].[卫生技术评估报告。液基细胞学在宫颈癌前病变筛查中的应用]
Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33.
9
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力:系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
10
Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS).用于经前综合征(PMS)的促性腺激素释放激素(GnRH)类似物。
Cochrane Database Syst Rev. 2025 Jun 10;6(6):CD011330. doi: 10.1002/14651858.CD011330.pub2.

引用本文的文献

1
Opportunistic Cervical Cancer Screening During Antenatal Visits: A Small Step Toward Early Detection.产前检查期间的机会性宫颈癌筛查:迈向早期发现的一小步。
Cureus. 2025 Aug 5;17(8):e89433. doi: 10.7759/cureus.89433. eCollection 2025 Aug.

本文引用的文献

1
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.一线帕博利珠单抗+化疗对比安慰剂+化疗用于持续性、复发性或转移性宫颈癌:KEYNOTE-826 的最终总生存结果。
J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1.
2
Cervical Cancer Prevention Efforts in India.印度的宫颈癌预防工作。
Indian J Gynecol Oncol. 2021;19(3):41. doi: 10.1007/s40944-021-00526-8. Epub 2021 Jun 2.
3
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计:全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.南亚女性人乳头瘤病毒类型分布的荟萃分析:对疫苗接种的启示
Vaccine. 2008 Jun 2;26(23):2811-7. doi: 10.1016/j.vaccine.2008.03.047. Epub 2008 Apr 11.